More recently, the safety and possible therapeutic effect of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 have been suggested in the EMMY (Empagliflozin in Myocardial Infarction) and PARADISE-MI (Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction) trials [37,38]. Here, SLC5A2 is linked to myocardial infarction.